Wall Street Zen Upgrades Rafael (NYSE:RFL) to “Hold”

Rafael (NYSE:RFL) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Rafael Price Performance

RFL stock opened at $2.11 on Friday. Rafael has a 1 year low of $1.12 and a 1 year high of $3.96. The company has a market cap of $109.72 million, a P/E ratio of -3.10 and a beta of 0.29. The stock’s fifty day moving average price is $2.16 and its 200-day moving average price is $1.58.

Institutional Trading of Rafael

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its position in Rafael by 72.9% in the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock worth $781,000 after acquiring an additional 190,179 shares during the period. Marshall Wace LLP bought a new stake in shares of Rafael during the 2nd quarter valued at $50,000. Cable Car Capital LP bought a new stake in shares of Rafael during the 2nd quarter valued at $173,000. Vanguard Group Inc. grew its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after acquiring an additional 133,024 shares during the period. Finally, Citadel Advisors LLC increased its stake in shares of Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares in the last quarter. 11.30% of the stock is owned by hedge funds and other institutional investors.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.